Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Inozyme Pharma Expands its Scientific Advisory Board
Inozyme Pharma Inc.April 1, 2021 GMT
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today changes to its scientific advisory board (SAB), including the addition of three leading key opinion leaders with specific expertise in the company’s lead indications:
W Charles O’Neill IV, M.D., Director of the Ultrasonography Program in the Renal Division at Emory University School of Medicine